# US 2013/0274194 A1 · Factor VIII-Fc Chimeric and Hybrid Polypeptides, and Methods of Use Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0274194 A1
- Document ID: US20130274194A1
- Status: Published application
- Kind: A1
- Application number: 13/793,783
- Filed: 2013-03-11
- Published: 2013-10-17
- Earliest claimed: 2009-12-06
- Assignees: Biogen Idec Hemophilia Inc.
- Applicants: Biogen Idec Hemophilia Inc.
- Inventors: Jennifer A. Dumont; Susan Low; Alan J. Bitonti; Glenn Pierce; Alvin Luk; Haiyan Jiang; Byron McKinney; Matt Ottmer; Jurg Sommer; Karen Nugent; Lian Li; Robert Peters
- Web page: https://patentgrep.com/patent/US20130274194A1

## CPC

- A61K 38/37: Factors VIII
- A61K 47/643: {Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]}
- A61K 47/6811: {the drug being a protein or peptide, e.g. transferrin or bleomycin}
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 41/00: Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- C07K 14/755: Factors VIII {, e.g. factor VIII C (AHF), factor VIII Ag (VWF)}
- C07K 16/46: Hybrid immunoglobulins (hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00)
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- Y02A 90/10: Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.

## Claims

### Claim at position 1

1-110. (canceled)

### Claim 111

A method of maintaining homeostasis in a human subject in need of a surgery comprising administering to the subject a therapeutic dose of a chimeric polypeptide comprising a long-acting Factor VIII (“FVIII”) polypeptide at a dosing interval,
wherein the therapeutic dose is about 35 IU/kg to about 50 IU/kg, and
wherein the dosing interval is 12 hours or longer.

### Claim 112 (depends on 111)

The method of claim 111, wherein a trough level of plasma Factor VIII:C in the subject after the administration is maintained above 3 IU/dl.

### Claim 113 (depends on 111)

The method of claim 111, wherein the administration prevents a bleeding episode in the subject.

### Claim 114 (depends on 111)

The method of claim 111, wherein the subject is in need of surgical prophylaxis, peri-operative management, or treatment for surgery.

### Claim 115 (depends on 111)

The method of claim 111, wherein the surgery is minor surgery, major surgery, tooth extraction, tonsillectomy, inguinal herniotomy, synovectomy, total knee replacement, craniotomy, osteosynthesis, trauma surgery, intracranial surgery, intra-abdominal surgery, intrathoracic surgery, or joint replacement surgery.

### Claim 116 (depends on 111)

The method of claim 111, wherein the surgery is an emergency surgery.

### Claim 117 (depends on 111)

The method of claim 111, wherein the therapeutic dose is about 35 IU/kg, about 40 IU/kg, about 45 IU/kg, or about 50 IU/kg.

### Claim 118 (depends on 111)

The method of claim 111, wherein the dosing interval is about 12 hours to about 24 hours, about 24 hours to about 36 hours, about 24 hours to about 48 hours, or about 24 hours to about 72 hours.

### Claim 119 (depends on 111)

The method of claim 111, wherein the dosing interval is about 12 hours to about 24 hours.

### Claim 120 (depends on 111)

The method of claim 111, wherein the long-acting FVIII polypeptide is pegylated FVIII.

### Claim 121 (depends on 111)

The method of claim 111, wherein the long-acting FVIII polypeptide comprises a FVIII portion and a second portion.

### Claim 122 (depends on 121)

The method of claim 121, wherein the second portion is an Fc portion or an albumin portion.

### Claim 123 (depends on 121)

The method of claim 121, wherein the long-acting FVIII polypeptide is a FVIIIFc monomer dimer hybrid.

### Claim 124 (depends on 121)

The method of claim 121, wherein the FVIII portion comprises full-length FVIII, mature FVIII, or FVIII with a full or partial deletion of the B domain.

### Claim 125 (depends on 111)

The method of claim 111, wherein a mean clearance (CL) (activity) in the subject is about 2.33±1.08 mL/hour/kg or less.

### Claim 126 (depends on 111)

The method of claim 111, wherein a mean residence time (MRT) (activity) in the subject is about 1.5 fold longer than the mean MRT of a polypeptide consisting of said FVIII portion.

### Claim 127 (depends on 111)

The method of claim 111, wherein a T½ (activity) in the subject is about 1.5 fold longer than the mean T½ (activity) of a polypeptide consisting of said FVIII portion.

### Claim 128 (depends on 111)

The method of claim 111, wherein a mean incremental recovery (K value) in the subject is about 90% of the mean incremental recovery of a polypeptide consisting of said FVIII portion.

### Claim 129 (depends on 111)

The method of claim 111, wherein a mean Vss (activity) in the subject is about 37.7 to 79.4 mL/kg.

### Claim 130 (depends on 111)

The method of claim 111, wherein a mean AUC/dose (activity) in the subject is about 19.2*h/dL per IU/kg to 81.7 IU*h/dL per IU/kg.

### Claim 131 (depends on 111)

The method of claim 111, wherein the dosing interval is 24 hours to 72 hours.
